Medscape

Botulinum Toxin Daxxify Gets FDA Nod for Cervical Dystonia

The US Food and Drug Administration (FDA) has expanded the indiction for daxibotulinumtoxinA-lanm injection (Daxxify, Revance Therapeutics) for the treatment of cervical dystonia in adults, the ...

Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsight

Recently published Cervical Dystonia Market Insights report includes a comprehensive understanding of current treatment practices, cervical dystonia emerging drugs, market share of individual ...
Medscape

Positive Topline Results for New Cervical Dystonia Treatment

DaxibotulinumtoxinA for Injection for treatment for cervical dystonia met the primary and all secondary endpoints in the phase 3 ASPEN-1 study, according to topline results released today by Revance ...
Business Wire

Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that Shanghai Fosun ...
FiercePharma

Revance pivots into therapeutics with cervical dystonia nod for Botox rival Daxxify

After debuting in the aesthetics market with Daxxify last year, Revance has made its way to the potentially lucrative therapeutic space. With a Monday FDA nod to treat cervical dystonia in adults, ...